Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA2 | P42262 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.37 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.34 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.34 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22324917 | 0.89 | EPHX2 (0.36) | GRIA2CYP1A2CYP2C9SLC6A2SLC6A4 | |
| SCHEMBL22324765 | 0.84 | L3MBTL1 (0.42) | GRIA2CYP1A2CYP2C9 | |
| SCHEMBL22324774 | 0.82 | CYP1A2 (0.42) | GRIA2CYP1A2CYP2C9BDKRB1SLC6A2 | |
| SCHEMBL22324961 | 0.82 | GRIA2 (0.42) | GRIA2CYP1A2CYP2C9BDKRB1SLC6A2 | |
| SCHEMBL22324830 | 0.81 | GRIA2 (0.38) | GRIA2CYP1A2CYP2C9 | |
| SCHEMBL22324880 | 0.79 | CYP1A2 (0.46) | GRIA2CYP1A2CYP2C9BDKRB1SLC6A2 | |
| SCHEMBL22324890 | 0.75 | SMN1; SMN2 (0.48) | MAPK1 | |
| Hydrochloric Acid SCHEMBL22325037 | 0.74 | SMN1; SMN2 (0.47) | MAPK1 | |
| SCHEMBL22324870 | 0.73 | ROCK2 (0.46) | DPP4DPP8DPP9DPP7 | |
| SCHEMBL22324937 | 0.71 | FAAH (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12479816-B2 | 20-HETE formation inhibitors | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2025-11-25 | — | — | US | disclosed |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-12 | — | — | US | disclosed |
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2022-05-12 | — | — | US | disclosed |
| WO-2020163689-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020163689-A1 | 20-HETE FORMATION INHIBITORS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2020-08-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144797-A1 | 20-HETE FORMATION INHIBITORS | CYP4A22, ALOX5, ALOX15 | GRIA2 1400/4885CYP1A2 41/4885CYP2C9 84/4885 |
| US-12479816-B2 | 20-HETE formation inhibitors | CYP4A22, ALOX5, ALOX15 | GRIA2 1400/4885CYP1A2 41/4885CYP2C9 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.